The Oasis Health Journal · Submitted July 21, 2026 · 8:17 AM ET

In 1965 a Dutch botanist named Cornelis Kalkman worked his way through the Old World species of Prunus and concluded that the genus Pygeum was not really a genus. He folded it into Prunus. The tree that had been called Pygeum africanum since the 1860s became Prunus africana, and it has been Prunus africana ever since. Kew still lists it that way. Pygeum africanum sits in the synonyms column, which in botany is a polite word for retired.

Sixty-one years later, go look at the shelf. It says Pygeum.

That is not a scandal. That is just a very slow memo.

The name is funnier than the supplement industry realizes

Joseph Gaertner coined the genus Pygeum in the 1700s, and he was not thinking about prostates. The word comes from the Greek pyge, meaning rump. The fruit of these trees is a small drupe, wider than it is long, split into two round lobes, and Gaertner decided the two lobes looked like a pair of glutes. So the plant got named after a backside. Two centuries later we started selling its bark for a gland in roughly the same zip code. Nobody planned that. Naming is just like that sometimes.

The tree has another common name, by the way. Red stinkwood. Marketing went with Pygeum.

The plant itself deserves better press than a capsule label gives it. Prunus africana is the tallest member of the entire Prunus genus, a canopy tree that runs 30 to 40 meters and grows in the montane forests of central and southern Africa and on Madagascar, somewhere between 900 and 3,400 meters up. It is a cousin of the cherry, the plum and the almond. Cut the wood fresh and it smells like bitter almond. The part that ends up in a bottle is the bark, extracted for its phytosterols and other fat-soluble compounds.

What the trials actually found

In 2002 Timothy Wilt and Areef Ishani published a Cochrane review of Pygeum africanum for benign prostatic hyperplasia, the noncancerous prostate enlargement that turns a night of sleep into a commute. They pooled 18 randomized controlled trials covering 1,562 men. Seventeen of the 18 were double blinded.

Men taking pygeum were more than twice as likely to report their overall urinary symptoms had improved (relative risk 2.1, with a 95 percent confidence interval of 1.4 to 3.1). Nocturia, the getting up at night part, dropped by 19 percent. Residual urine volume, meaning what stays in the bladder after you were fairly sure you were finished, dropped 24 percent. Peak urine flow rose 23 percent. Side effects were mild and no more common than placebo. Thirteen percent of the pygeum group dropped out, against 11 percent of the placebo group, which is a rounding error wearing a lab coat.

That is a good looking box score. Here is the rest of it.

The average trial ran 64 days. The longest ran 122. Benign prostatic hyperplasia is a condition men carry for decades, and the entire evidence base is measured in weeks. Only one of the 18 trials described how it concealed treatment allocation, which is the step that keeps a study honest about who got what. And there were zero trials putting pygeum head to head against the drugs urologists actually prescribe, the alpha blockers and the 5-alpha reductase inhibitors. So we know pygeum beat nothing. We do not know how it does against something.

Cochrane said so plainly: a standardized preparation may be a useful option, and more trials are needed. Twenty-four years on, those trials have mostly not shown up. A 2016 review in Current Urology Reports looked at phytotherapy for this condition and concluded pygeum offered no benefit. The American Urological Association guideline is blunter still. The studies vary too much in method and quality, so a positive recommendation is not warranted.

Both things are true at once. The trials that exist came out mostly favorable. There are not enough of them, they were short, they were old, and the referee has not raised anyone's hand.

Which is a strange place to land for something Europe has treated as a medicine since 1969. The same bark extract has been sold in France and across central Europe as a registered pharmaceutical for mild to moderate prostate symptoms for over half a century. In the United States it is a supplement. Same tree, same extract, different aisle.

The part that does not fit on a label

The bark comes off a slow-growing wild forest tree, and for a long stretch it came off badly. In the 1990s an estimated 35,000 debarked trees were being processed a year. Take too much bark and the tree dies, which is a fairly permanent side effect. Prunus africana was listed on CITES Appendix II on 16 February 1995 specifically because the trade was outrunning the forest, and the IUCN Red List still classifies the species as Vulnerable with a declining population trend.

So if you buy this one, sourcing is not a footnote. Sourcing is the whole question of whether there is a tree next decade.

It is also part of why we do not warehouse this category. Every order of pygeum bark extract is pulled fresh from professional-grade suppliers when you place it, instead of being picked off a pallet that has been quietly losing potency in a distribution center since last spring. It ships slower. It arrives stronger. We think that is the correct trade.

Practically, pygeum rarely travels alone. It is most often paired with saw palmetto, and standardized pygeum extracts are usually measured by their plant sterol content, which is where much of the proposed activity is thought to sit. Most prostate formulas on a shelf are some arrangement of those two plus zinc.

One thing worth saying without a joke attached. Getting up four times a night to urinate is a symptom, and symptoms are not diagnoses. Urinary changes in men past 50 can come from benign prostatic hyperplasia, and they can come from other things that a bark extract will not fix and should not be allowed to mask. Get the workup first. Have the supplement conversation second, with someone who is holding your chart.

And if you ever want to be insufferable at dinner: the tree is Prunus africana. Has been since 1965.

This article is for education only. It is not medical advice, and it is not a substitute for a conversation with your own clinician.

Pygeum Is a Name Botany Retired in 1965. The Supplement Aisle Never Got the Memo.

The name is funnier than the supplement industry realizes

What the trials actually found

The part that does not fit on a label

Sources

Leave a comment

Save 10% off your first purchase

The name is funnier than the supplement industry realizes

What the trials actually found

The part that does not fit on a label

Sources